HER2-Negative Breast Cancer Epidemiology Market is expected to reach USD 1.31 Million by 2034

Overview
HER2-negative breast cancer is the most common breast cancer subtype, accounting for approximately 70-75% of all breast cancer cases worldwide. It includes:
• Hormone Receptor Positive / HER2-Negative (HR+/HER2-): ~65% of all cases
• Triple-Negative Breast Cancer (TNBC): ~10-12% of all cases
The disease burden continues to grow due to rising screening rates, lifestyle risk factors, improved diagnostic technologies, and aging populations.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73664

In 2024, there are an estimated 1.78 million women globally living with HER2-negative breast cancer, with incidence increasing across high-income and emerging regions.

Key Epidemiological Insights
• HER2-negative accounts for the majority of global breast cancer cases.
• HR+/HER2- incidence is increasing due to hormonal and reproductive risk factors.
• Triple-Negative BC remains aggressive, with higher incidence in younger and genetically predisposed populations.
• Improved mammography and molecular profiling enable more accurate diagnosis.
• Survival rates vary widely by subtype, stage, and access to treatment.

Global Disease Burden: 2024 Snapshot
Incidence
• Total breast cancer incidence globally: ~2.3 million
• HER2-negative share: ~1.04 million incident cases
o HR+/HER2-: ~870,000
o TNBC: ~170,000

Prevalence
• Global prevalent HER2-negative cases: ~1.78 million
• Long-term survivorship is highest in HR+/HER2- due to slow tumor biology and effective endocrine therapy.

Mortality
• HER2-negative breast cancer mortality represents ~55% of global breast-cancer deaths.
• TNBC alone accounts for ~18-20% of global breast cancer mortality despite lower incidence.

Patient Demographics
Age Distribution
• HR+/HER2-: Most common in women aged 50-70
• TNBC: Higher incidence in women aged Less than 50, especially Black, Hispanic, and South Asian populations
Genetic Factors
• TNBC strongly associated with BRCA1/BRCA2 mutations
• Family history increases HER2-negative BC risk significantly
Risk Factors
• Reproductive factors (late pregnancy, low breastfeeding rates)
• Obesity and physical inactivity
• Alcohol consumption
• Hormone replacement therapy (in HR+/HER2- cases)

Disease Segmentation
By Subtype
• HR+/HER2- Breast Cancer (largest segment)
o High prevalence
o Strong response to endocrine therapy
• Triple-Negative Breast Cancer (TNBC)
o Higher aggressiveness
o Limited targeted therapy options
o Higher recurrence rates

By Stage at Diagnosis
• Stage I-II: ~55-60% (higher in developed countries due to screening)
• Stage III: ~25-30%
• Stage IV: ~10-15%

By Gender
• Women: ~99%
• Men: less than 1% but rising awareness is increasing detection rates

Explore Full Report here: https://exactitudeconsultancy.com/reports/73664/her2-negative-breast-cancer-epidemiology-market

Regional Epidemiology
North America
• High incidence due to widespread screening
• Higher TNBC prevalence among African American women
• Strong availability of endocrine therapies and molecular diagnostics
• 2024 incidence: ~215,000 HER2- cases
Europe
• Rising HR+/HER2- due to aging population and lifestyle factors
• Well-established cancer registries
• Incidence: ~240,000 cases in 2024
Asia Pacific
• Fastest-growing region
• Increasing incidence driven by lifestyle changes and urbanization
• TNBC more common compared to Western populations
• Incidence: ~350,000 HER2- cases in 2024
Latin America
• Moderate incidence but higher late-stage diagnoses
• TNBC rates are elevated in some populations
• Incidence: ~85,000 cases
Middle East & Africa
• Lower screening access
• High share of late-stage presentations
• TNBC more common
• Incidence: ~65,000 cases

Trends Shaping HER2-Negative Breast Cancer Epidemiology
• Expansion of biomarker and genomic testing improving classification accuracy
• Rapid adoption of digital mammography and AI-enabled screening systems
• Increased detection of early-stage HR+ disease, improving survival
• Higher TNBC research activity influencing future therapeutic landscapes
• Greater global awareness campaigns, especially in emerging markets
• Rise of male breast cancer diagnosis, though still rare

Forecast (2025-2034)
• Global annual incident cases will rise from 1.04 million (2024) to 1.31 million (2034)
• Growth driven largely by APAC, Middle East, and Latin America
• HR+/HER2- will continue dominating due to demographic and lifestyle shifts
• TNBC cases will also increase due to better molecular diagnostics
• Early-stage diagnoses expected to rise with population-wide screening programs

Conclusion
HER2-negative breast cancer remains the most prevalent breast cancer subtype globally, with a rapidly growing diagnosed population and increasing demand for early detection and long-term treatment. With more than 1.78 million prevalent cases and rising incidence forecast through 2034, countries must invest in:
• Screening and early detection
• Molecular diagnostics (ER/PR testing, genomic profiling)
• Access to endocrine therapy and chemotherapy
• Improved TNBC clinical infrastructure
• Survivorship and supportive care programs
This epidemiological landscape forms the basis for future market growth, clinical development, and healthcare policy planning across major global regions.

This report is also available in the following languages : Japanese (HER2陰性乳がん疫学市場), Korean (HER2 음성 유방암 역학 시장), Chinese (HER2阴性乳腺癌流行病学市场), French (Marché de l'épidémiologie du cancer du sein HER2-négatif), German (Markt für Epidemiologie von HER2-negativem Brustkrebs), and Italian (Epidemiologia del mercato del cancro al seno HER2-negativo), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73664

Our More Reports:

U.S. Companion Diagnostics Oncology Market
https://exactitudeconsultancy.com/reports/50380/u-s-companion-diagnostics-oncology-market

Europe Breast Cancer Market
https://exactitudeconsultancy.com/reports/50529/europe-breast-cancer-market

U.S. Cancer Immunotherapy Market
https://exactitudeconsultancy.com/reports/50644/u-s-cancer-immunotherapy-market

Estrogen Receptor Modulators Market
https://exactitudeconsultancy.com/reports/50752/estrogen-receptor-modulators-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.